Immuno-oncology has transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells. This session explores tumor immunology, immune escape, checkpoint inhibition, cellular immunotherapies, biomarkers, resistance mechanisms, and strategies to improve the effectiveness and safety of immune-based treatments.
Abstract Scope and Participation
Abstracts may include tumor immunology, checkpoint inhibitors, CAR-T therapy, TCR and TIL therapies, immune biomarkers, combination immunotherapy, immune resistance, tumor-immune interactions, and immune-related toxicities. Immunologists, oncologists, translational scientists, researchers, and biotechnology professionals are encouraged to participate.
Objective: This study aimed to investigate the role of RGS2 in immune regulation and its impact on the efficacy of PD-1/PD-L1 blockade therapy in lung cancer (LC), as well as to explore the…
Neoadjuvant immunotherapy with anti-programmed death-1 (neo-antiPD1) has revolutionized perioperative treatment for improving the overall survival (OS) of patients with early-stage lung cancer.…
Breast cancer is the most prevalent malignancy in women worldwide and remains a leading cause of cancer-related mortality. Immune system controls tumor progression but is often suppressed in breast…
MHC class I complexes can present antigenic peptides that have a sequence produced by post-translational mechanisms such as peptide splicing. Some examples of tumour-associated spliced epitopes have…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Cancer Immunology & Immuno-Oncology work, reviewed by the scientific committee.
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Cancer Immunology & Immuno-Oncology research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Cancer Immunology & Immuno-Oncology track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Cancer Immunology & Immuno-Oncology. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Cancer researchers and clinicians, educators and students with an interest in Cancer Immunology & Immuno-Oncology are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. CIOC 2027 is a hybrid conference — attend the Cancer Immunology & Immuno-Oncology track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
